Glucocorticoids (cortisol in humans, corticosterone in rodents) are essential steroid hormones produced by the adrenal cortex that regulate numerous physiological processes including metabolism, immune function, cardiovascular function, and brain activity. While acute glucocorticoid release is adaptive and necessary for survival, chronic elevation of these hormones—particularly as occurs with prolonged stress—has emerged as a significant contributor to neurodegenerative processes [1].
The hypothalamic-pituitary-adrenal (HPA) axis represents the central neuroendocrine system governing glucocorticoid production. Under normal conditions, this axis operates in a tightly regulated circadian rhythm, with cortisol levels peaking in the early morning and reaching nadirs during nighttime sleep. However, in neurodegenerative diseases, this rhythm becomes dysregulated, leading to sustained elevation of glucocorticoids that can accelerate pathology.
The glucocorticoid receptor (GR, encoded by NR3C1) and mineralocorticoid receptor (MR, encoded by NR3C2) mediate glucocorticoid signaling in the brain. These receptors have distinct affinities for glucocorticoids—MR has high affinity for cortisol while GR requires higher concentrations—allowing for differential signaling depending on glucocorticoid concentration. Both receptors are widely expressed in brain regions critical for cognition and movement, including the hippocampus, prefrontal cortex, basal ganglia, and substantia nigra.
The HPA axis operates as a classic endocrine feedback loop. Stress—physical or psychological—triggers hypothalamic paraventricular nucleus (PVN) neurons to release corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) into the hypophyseal portal system. These hormones stimulate the anterior pituitary to secrete adrenocorticotropic hormone (ACTH), which travels through the bloodstream to the adrenal cortex, triggering cortisol synthesis and release.
Cortisol then acts on multiple target tissues, including the brain, to mount an appropriate stress response. Critically, cortisol exerts negative feedback on both the hypothalamus and pituitary to dampen further CRH and ACTH release, thereby terminating the stress response. This feedback occurs through GR in the PVN and pituitary, and this regulatory mechanism can become impaired in neurodegeneration.
In Alzheimer's disease, HPA axis dysregulation manifests as:
Similar patterns are observed in Parkinson's disease, where HPA axis dysfunction correlates with disease severity and cognitive impairment [3].
The classic glucocorticoid signaling pathway involves genomic effects mediated by cytoplasmic GR [4]:
Target genes relevant to neurodegeneration include:
Glucocorticoids also exert rapid effects that cannot be explained by transcriptional mechanisms [5]:
These non-genomic effects occur within minutes—much faster than genomic effects that require hours. They are particularly relevant to acute stress effects on cognition and behavior.
Glucocorticoids potentiate amyloid-β pathology through multiple mechanisms [6]:
The relationship appears bidirectional: amyloid pathology itself can dysregulate the HPA axis, creating a feedforward loop that accelerates disease progression.
Chronic glucocorticoid exposure exacerbates tau pathology through several pathways [7]:
Evidence from both animal models and human studies supports a role for glucocorticoids in accelerating tau pathology progression.
The hippocampus is particularly vulnerable to glucocorticoid excess [8]. Glucocorticoids impair hippocampal function through:
These effects help explain the strong correlation between elevated cortisol and cognitive decline in AD patients.
Glucocorticoids have complex effects on neuroinflammation [9]:
This dysregulated inflammation contributes to neuronal dysfunction and death.
Parkinson's disease is associated with significant HPA axis abnormalities [10]:
These abnormalities correlate with non-motor symptoms including sleep disturbance, depression, and cognitive impairment.
Glucocorticoids interact with the dopaminergic system in multiple ways:
Stress and glucocorticoid exposure can exacerbate motor symptoms in PD, likely through these interactions.
Glucocorticoid-mitochondria interactions are particularly relevant to PD pathogenesis [11]:
Given the central role of mitochondrial dysfunction in PD, glucocorticoid effects on mitochondria represent a significant disease mechanism.
Mifepristone (RU-486) is the most well-studied GR antagonist:
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) converts inert cortisone to active cortisol in target tissues, including the brain [12]:
Several pharmaceutical companies have advanced 11β-HSD1 inhibitors to clinical testing.
FKBP5 is a co-chaperone that influences GR sensitivity and function [13]:
Given the importance of glucocorticoid circadian rhythm disruption [14]:
Related pathways:
Related genes:
Related diseases:
Carroll RK, et al. Glucocorticoids in aging and neurodegeneration. Prog Neuropsychopharmacol Biol Psychiatry. 2022. ↩︎
Sapolsky RM. Cortisol in Alzheimer's disease. Neurobiol Aging. 2003. ↩︎
Wang L, et al. HPA axis dysregulation in PD. Mov Disord. 2024. ↩︎
Oakley RH, Cidlowski JA. Glucocorticoid receptor signaling. Annu Rev Physiol. 2012. ↩︎
Pavlović DM, et al. GR in synaptic plasticity. Neuroscientist. 2014. ↩︎
Carroll JC, et al. Glucocorticoids and amyloid production. J Neurosci. 2007. ↩︎
Green PS, et al. Glucocorticoids and tau pathology. J Neurosci. 2011. ↩︎
Poplawski M, et al. Glucocorticoids and hippocampal dysfunction. Psychoneuroendocrinology. 2019. ↩︎
Liu X, et al. GR in neuroinflammation. Brain Behav Immun. 2023. ↩︎
Charlton BG. HPA axis in Parkinson's disease. J Neural Transm. 2008. ↩︎
Johnson BC, et al. Glucocorticoid-mitochondria interaction. Cell Death Discov. 2024. ↩︎
Chen W, et al. 11beta-HSD1 inhibitors in AD. Alzheimers Res Ther. 2024. ↩︎
Yu E, et al. FKBP5 and tau pathology. Acta Neuropathol Commun. 2023. ↩︎
Smith AG, et al. Circadian glucocorticoid rhythm disruption. Nat Rev Endocrinol. 2024. ↩︎